{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:23:18Z","timestamp":1791181398076,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T00:00:00Z","timestamp":1358726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Panobinostat (<jats:styled-content style=\"fixed-case\">LBH<\/jats:styled-content>589), a novel histone deacetylase inhibitor (<jats:styled-content style=\"fixed-case\">HDAC<\/jats:styled-content>i), was evaluated in a phase I study of patients with primary myelofibrosis (<jats:styled-content style=\"fixed-case\">PMF<\/jats:styled-content>) and post\u2010essential thrombocythaemia\/polycythaemia vera\u2010related myelofibrosis (Post\u2010<jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PV MF<\/jats:styled-content>). Eighteen patients (<jats:styled-content style=\"fixed-case\">PMF<\/jats:styled-content> 56%; Post\u2010<jats:styled-content style=\"fixed-case\">PV MF<\/jats:styled-content> 28%; Post\u2010<jats:styled-content style=\"fixed-case\">ET MF<\/jats:styled-content> 17%) were treated in three cohorts at oral doses of (i) 20, (ii) 30, and (iii) 25\u00a0mg three times weekly consecutively. Reversible thrombocytopenia was the dose\u2010limiting toxicity. Five patients (two in Dose Cohort 1, one in Dose Cohort 2 and two in Dose Cohort 3) received six or more cycles and were evaluable for response assessment. After the sixth cycle, three of these five patients achieved clinical improvement (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) with 100% reduction in palpable splenomegaly from baseline, and two patients experienced stable disease. Panobinostat therapy was also associated with improvement in the degree of anaemia in two of the five patients. Of the three patients who achieved <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> after six cycles, one patient achieved a near complete remission after 15 cycles of treatment and another patient had resolution of marrow fibrosis after 16 cycles. We conclude that panobinostat is a well\u2010tolerated, clinically active treatment for <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content> patients, regardless of <jats:italic><jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>2 <\/jats:italic><jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>617<jats:styled-content style=\"fixed-case\">F<\/jats:styled-content> status, and most effective when given at low doses over long periods of time.<\/jats:p>","DOI":"10.1111\/bjh.12220","type":"journal-article","created":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T11:08:41Z","timestamp":1358766521000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post\u2010polycythaemia vera\/essential thrombocythaemia myelofibrosis (post\u2010PV\/ET MF)"],"prefix":"10.1111","volume":"161","author":[{"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[{"name":"Division of Hematology Tisch Cancer Institute Mount Sinai School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hematology Tisch Cancer Institute Mount Sinai School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timmy","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology Tisch Cancer Institute Mount Sinai School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Petersen","sequence":"additional","affiliation":[{"name":"Division of Pathology Mount Sinai School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsivia","family":"Hochman","sequence":"additional","affiliation":[{"name":"Division of Biostatistics New York University School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[{"name":"Division of Hematology Tisch Cancer Institute Mount Sinai School of Medicine New York NY USA"},{"name":"Division of Pathology Mount Sinai School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Biostatistics New York University School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Division of Hematology Tisch Cancer Institute Mount Sinai School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.02.019"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0240"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"630a","DOI":"10.1182\/blood.V116.21.630.630","article-title":"A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis","volume":"116","author":"De Angelo D.J.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.04.007"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08355.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.03.003"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08266.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0572"},{"key":"e_1_2_9_13_1","first-page":"118","article-title":"The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update","volume":"2","author":"Silverman L.R.","year":"2008","journal-title":"Ecancermedicalscience"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"907a","DOI":"10.1182\/blood.V110.11.907.907","article-title":"Phase IA\/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies","volume":"110","author":"Spencer A.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4508"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12220","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T18:55:08Z","timestamp":1697655308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/bjh.12220"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12220","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,21]]},"assertion":[{"value":"2012-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}